Clinical analysis of 206 cases of hemorrhage complications after percutaneous renal biopsy

Objective To investigate whether hemostatic drugs can effectively reduce hemorrhage complications during the time of percutaneous native renal biopsy.Methods 206 cases undergoing percutaneous native renal biopsy in our department were collected in the period of 2010.1-2017.8. 101 cases were treated with hemostatic drugs (case group), and 105 cases were not treated with any hemostatic drugs. We matched sex and age, and observed the morbidity rate of gross hematuria and severe hemorrhage complications (gross hematuria given red blood cell transfusion, obvious renal arteriovenous fistula, or selective renal artery embolization) in 2 groups. The difference in hemorrhage complications between case group and control group was compared statistically. Results Four cases in case group had gross hematuria (1 case of IgA nephropathy, 1 case of idiopathic membranous nephropathy, 1 case of mesangial proliferative glomerulonephritis and 1 case of renal amyloidosis). Among them, 1 case was given transfusion of red blood cells, and 1 case selective renal artery interventional embolization. Six cases in control group had gross hematuria (2 cases of IgA nephropathy, 1 case of idiopathic membranous nephropathy, 1 case of minimal change glomerulopathy, 1 case of lupus nephritis and 1 case of renal amyloidosis). Among them, 2 cases were given transfusion of red blood cells, 2 cases had arteriovenous fistula, and 1 case was given interventional embolization. The incidence of gross hematuria and severe hemorrhage complications in case group was lower than that in control group (3.76% vs. 5.71%, P=0.748; 1.98% vs. 4.76%, P=0.446).Conclusions Application of conventional hemostatic drugs in percutaneous native renal biopsy did not reduce the incidence of gross hematuria and severe hemorrhage complications.